ClinicalTrials.gg
Drug

Ustekinumab clinical trials

Also written Stelara, CNTO 1275 and ABP 654.

studies test it
101
open now
11
in phase 3
39
first study started
2003

How each study uses Ustekinumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Ustekinumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Sept 2009 · STELARA · BLA 125261 (FDA, Drugs@FDA)
European Union
16 Jan 2009 · Stelara · EMEA/H/C/000958 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ustekinumab
61
Ustekinumab 90 mg
10
Ustekinumab 45 mg
7
dose escalation only in arm 2
2
Ustekinumab IV
2

Brand

Stelara
33

Development codes

CNTO 1275
7
ABP 654
2

Studies by the year they started

101 studies that test it; most in 2021 (14)

Studies that test Ustekinumab, by start year
YearStudies
20031
20042
20053
20071
20083
20095
20104
20114
20126
20133
20145
20158
20163
20174
20186
20194
202011
202114
20225
20242
20254
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
17
Phase 2
34
Phase 3
39
Phase 4
15
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 57 · Other 44

Janssen Research & Development, LLC (28) · Centocor, Inc. (10) · Janssen Pharmaceutical K.K. (4) · Assistance Publique - Hôpitaux de Paris (3) · University of British Columbia (2) · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW (2) · Janssen-Cilag Ltd. (2) · Amgen (2)

Often tested with

Tested in the same studies.

Guselkumab (7) · Secukinumab (7) · Adalimumab (5) · Methotrexate (4) · Etanercept (4) · Infliximab (4) · Golimumab (3) · Certolizumab Pegol (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Ustekinumab is the comparator. A study of two new drugs counts under both.

  • 2Risankizumab · AbbVie, First Affiliated Hospital of Wenzhou Medical University · next primary completion Feb 2028
  • 1Upadacitinib · Sixth Affiliated Hospital, Sun Yat-sen University · next primary completion Dec 2026
  • 1Deucravacitinib · Bristol-Myers Squibb · next primary completion Jan 2031
Reaching primary completion within a year · 5, 1 in phase 3

Studies that test Ustekinumab, phase 3 first.

Studies

Open first, then newest update. How each study uses Ustekinumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 101

See all 101 studies that test Ustekinumab →

Given beside what is tested · 15 — Ustekinumab is usual care or a partner of the new treatment
As the comparator · 22 — what is tested is compared with Ustekinumab

Showing 20 of 22.

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call Ustekinumab · ClinicalTrials.gg INT006608

  • MeSH (NLM) D000069549UstekinumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) FU77B4U5Z0USTEKINUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 847083Confirmed FDA, Wikidata
  • Wikidata Q420305ustekinumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C84237UstekinumabOne source FDA
  • DrugBank DB05679One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.